ReviewFrontiers in cell and developmental biology2026
Targeting ubiquitin-specific peptidase 22 in solid tumours: from ubiquitination to immunotherapy.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a deubiquitinating enzyme, the function of ubiquitin-specific peptidase 22 (USP22) in tumours has attracted increasing attention. However, the regulatory mechanism underlying USP22's tumour biological processes has not yet been thoroughly elucidated. Moreover, considering the importance of USP22 in immune regulation and clinical treatment, targeting USP22 to prevent tumour biological processes and improve immunotherapy is worthy of attention. Given the significance of USP22 in immune cell function and tumour progression, clarifying the molecular regulatory network of USP22 in different types of tumours is necessary. In this review, we summarise how USP22 regulates tumour biology and analyse the key role of USP22 in immune regulation to provide new insights into novel therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.